Creative Medical Technology Holdings

Creative Medical Technology Holdings, Inc. (NASDAQ: CELZ), headquartered in Phoenix, AZ, is a clinical-stage biotechnology company pioneering regenerative medicine and immunotherapies to address unmet needs in immunology, endocrinology, urogynecology, and orthopedics. With a robust portfolio of over 60 patents, the company develops innovative cell-based therapies to improve patient outcomes and quality of life through minimally invasive, regenerative approaches.

Mission: To unlock the potential of regenerative technologies by advancing disruptive platforms—including supercharged autologous therapies, enhanced allogeneic cells, reprogrammed cells, and rapid autologous treatments—that provide novel solutions for chronic diseases and immune disorders.

Leadership:

• Timothy Warbington, CEO & Co-Founder: Healthcare executive with over 12 years of experience leading biotech innovations.
• Donald Dickerson, CFO: Oversees financial strategy, driving funding and growth initiatives.
• Thomas Ichim, Chief Science Officer: Expert in stem cell and immunotherapy research, guiding scientific development.
• Courtney Bartlett, Director of Clinical Development: Manages trial progression and regulatory affairs.

Pipeline: Focused on high-impact therapies in early to Phase II stages, including:

• AlloStem: For Type 1 diabetes reversal.
• AlloStemSpine (CELZ-201/DDT): Regenerative treatment for chronic lower back pain (FDA Fast Track Designation, August 2025).
• OvaStem: Stem cell therapy for infertility and ovarian health.
• ImmCelz Platform: Immunotherapies for autoimmune diseases, expanded via iPSC collaborations with Greenstone Biosciences (February 2025); recent patents cover Type 1 diabetes (expires 2043) and heart failure (expires 2042).

Recent highlights include securing $4.2 million in warrant exercises (October 2025) and initiating AI-driven diagnostics for biologic exposures.